✓
Open
1 Sep 2025
✓
Close
3 Sep 2025
3
Allotment
—
✓
Listing
Tue, Sep 9, 2025
Price Band
₹120 to ₹126
Issue Size
1,00,00,000 shares (agg. up to ₹126 Cr)
Lot Size
119 Shares
Listing Date
Tue, Sep 9, 2025
Latest GMP
₹9
Est. Gain
7.14%
✦ AI Insight
GMP Trend
09-09-2025₹9Est. ₹135+7.14%
08-09-2025₹9Est. ₹135+7.14%
07-09-2025₹9Est. ₹135+7.14%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 57.53x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 381.76 | 352.12 | 374.06 |
| Total Income | 276.09 | 281.61 | 262.70 |
| Profit After Tax | 10.50 | 3.63 | -2.11 |
| EBITDA | 61.05 | 58.76 | 56.31 |
| NET Worth | 96.39 | 66.29 | 62.88 |
| Reserves and Surplus | 67.56 | 39.46 | 36.05 |
| Total Borrowing | 195.00 | 205.23 | 215.66 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹14.73 (-3.22%) |
| Senores Pharmaceuticals Ltd. | Mainboard | ₹582.11 Cr | ₹391 | 39.77 | ₹557.80 | +42.66% | ₹1,405.10 (-3.68%) |
| Sai Life Sciences Ltd. | Mainboard | ₹3,042.62 Cr | ₹549 | 126.42 | ₹764.65 | +39.28% | ₹1,272.00 (-1.60%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹67.20 (-8.57%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹282.15 (-2.71%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹278.00 (-1.77%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹165.65 (-0.21%) |
| Amwill Health Care Ltd. | SME | ₹59.98 Cr | ₹111 | 13.81 | ₹93.25 | -15.99% | ₹43.39 (+3.04%) |
| Sat Kartar Shopping Ltd. | SME | ₹33.80 Cr | ₹81 | 14.87 | ₹161.55 | +99.44% | ₹126.60 (-2.62%) |
| Onyx Biotec Ltd. | SME | ₹29.34 Cr | ₹61 | 26.81 | ₹56.75 | -6.97% | ₹37.60 (-4.93%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat | 70.00 |
| 2 | Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat | 30.13 |
| 3 | General Corporate Purposes | 6.60 |
| 4 | Issue Expenses | 19.26 |
| Total | 126.00 |
About Amanta Healthcare IPO
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products, specifically parenteral products, which are packaged in plastic containers utilizing Aseptic Blow-Fill-Seal (“ABFS”) and Injection Stretch Blow Moulding (“ISBM”) technologies. The company is also a manufacturer of medical devices. The company manufactures fluid therapy formulations, including IV fluids, diluents, ophthalmic solutions, and respiratory care products. It also offers irrigation solutions, first-aid products, and eye lubricants in the medical device segment. The company markets products through three business units: National sales, International sales and Product partnering with various foreign and Indian pharmaceutical companies. The company manufactures over 45 generic products, marketing them under their brands in India through 320 distributors and stockists. The company sells products in Africa, Latin America, the UK, and beyond. Its products are registered in 19 countries and comply with various regulations. In Fiscal 2025, the company exported branded products to 21 cou
Contact Details
Amanta Healthcare Ltd. Address8th Floor, Shaligram CorporatesC.J. MargAmbliAhmedabad, Gujarat, 380058079 67777600cs@amanta.co.inVisit Website